Serum vascular endothelial growth factor is a candidate biomarker ofmetastatic tumor response to ex vivo gene therapy of renal cell cancer

Angelo A. Baccala, Hua Zhong, Shirley M. Clift, William G. Nelson, Fray F. Marshall, Theodore J. Passe, Neil B. Gambill, Jonathan W. Simons

Research output: Contribution to journalArticlepeer-review

Abstract

We report the close correlation between changes in serum immunoreactive vascular endothelial growth factor 165 (iVEGF165) levels and metastatic tumor burden measured by computed tomography scan before treatment, during the antitumor response, and during early progression in a patient treated with ex vivo gene therapy for renal cell carcinoma. With the researcher blinded to outcome, iVEGF levels were measured in archived serum samples from a patient with metastatic renal cell carcinoma who demonstrated a 7-month partial remission to treatment with autologous, irradiated human GM-CSF gene transduced tumor vaccine. Although a spontaneous regression could not be formally excluded in this patient, the appearance of 20 new pulmonary metastases on computed tomography scan after nephrectomy and before vaccination indicates that if spontaneous regression occurred, it took place at the start of vaccine treatment.

Original languageEnglish (US)
Pages (from-to)327-332
Number of pages6
JournalUrology
Volume51
Issue number2
DOIs
StatePublished - Feb 1 1998
Externally publishedYes

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Serum vascular endothelial growth factor is a candidate biomarker ofmetastatic tumor response to ex vivo gene therapy of renal cell cancer'. Together they form a unique fingerprint.

Cite this